Click on headlines below to download research
Termination of coverage
Termination of coverage | 30/03/2021
Edison Investment Research is terminating coverage on EJF Investments (EJFI), ROVI Laboratorios Farmaceuticos (ROVI) and SDX Energy (SDX). Please note…
2021: A pinnacle year
Laboratorios Farmacéuticos ROVI | 10/03/2021
Laboratorios Farmacéuticos ROVI (ROVI) has reported a strong set of FY20 results, with all pillars of the business contributing to revenue growth…
All good things come in threes
Laboratorios Farmacéuticos ROVI | 10/12/2020
Laboratorios Farmacéuticos ROVI’s (ROVI’s) recent capital markets day (CMD) highlighted the strong positioning of its three key franchises.…
Momentum continues across key franchises
Laboratorios Farmacéuticos ROVI | 11/11/2020
Reported 9M20 numbers highlight continual strength in sales across key franchises and ongoing margin expansion. ROVI reported operating revenue of €302.1m…
Top-line growth, significant margin expansion
Laboratorios Farmacéuticos ROVI | 29/07/2020
Laboratorios Farmacéuticos ROVI reported H120 operating revenue of €191.1m (+8% y-o-y), driven by strong growth in heparins (+23% to €104.0m)…
COVID-19 stockpiling positive impact
Laboratorios Farmacéuticos ROVI | 18/05/2020
Laboratorios Farmacéuticos ROVI (ROVI) reported Q120 operating revenue of €101.0m (+23% y-o-y), driven by strong growth both in the speciality…
Executive interview
Executive interview - Laboratorios Farmacéuticos ROVI | 06/04/2020
ROVI is a profitable speciality healthcare company that markets ~40 proprietary and in-licensed products across nine core franchises, mainly in its domestic…
Investing for future growth
Laboratorios Farmacéuticos ROVI | 28/02/2020
Laboratorios Farmacéuticos ROVI has reported a strong set of FY19 results, with all pillars of the business contributing to revenue growth of 26%…
Multiple growth drivers lie ahead
Laboratorios Farmacéuticos ROVI | 04/12/2019
Following Laboratorios Farmacéuticos ROVI’s (ROVI’s) recent investor day, we have reviewed our near-term forecasts. Specifically, we…